CABA-V7:针对AR-V7阳性前列腺癌患者卡巴他赛治疗的前瞻性生物标志物选择试验
CABA-V7是一项前瞻性、多中心、单臂II期临床试验,纳入既往接受过多西他赛和雄激素剥夺治疗的mCRPC患者,评估卡巴他赛在CTC-based AR-V7阳性患者中的PSA应答率。结果显示仅12%的患者获得PSA应答,AR-V7阳性预测较差的总生存期,但卡巴他赛治疗的AR-V7阳性患者与接受标准治疗的AR-V7阴性患者总生存期相似。
要点
- CTC-based AR-V7阳性mCRPC患者接受卡巴他赛后PSA应答率仅12%。
- CTC-based AR-V7状态和二分法CTC计数为基线独立预后标志物。
- AR-V7阳性预测较差总生存期,但卡巴他赛治疗者与AR-V7阴性标准治疗者总生存期相似。
核心结论
- AR-V7阳性预测较差的总生存期(OS)。
- 卡巴他赛治疗的AR-V7阳性患者与缺乏AR-V7阳性、接受卡巴他赛作为标准治疗的患者,总生存期似乎相似。
- 尽管应答率低,卡巴他赛可能仍是这一预后不良的AR-V7阳性患者群体的有效治疗。
研究设计与样本
- 前瞻性、多中心、单臂II期临床试验(CABA-V7)。
- 纳入既往接受过多西他赛和雄激素剥夺治疗的mCRPC患者。
- 基于CTC的AR-V7表达阳性患者接受卡巴他赛治疗,并采集液体活检进行基因组分析。
主要发现
- 卡巴他赛被发现有适度疗效,仅12%的患者获得PSA应答。
- 基因组分析显示,基于CTC的AR-V7表达与其他已知mCRPC相关改变无关。
- 基于CTC的AR-V7状态和二分法CTC计数在基线被观察为独立预后标志物。
临床怎么用
- 作者认为,尽管应答率低,卡巴他赛可能仍是这一预后不良的AR-V7阳性患者群体的有效治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) patients with positive AR-V7 expression in their circulating tumour cells (CTCs) rarely derive benefit from abiraterone and enzalutamide. DESIGN: We performed a prospective, multicenter, single arm phase II clinical trial (CABA-V7) in mCRPC patients previously treated with docetaxel and androgen deprivation therapy. OBJECTIVE: In this trial, we investigated whether cabazitaxel treatment resulted in clinically meaningful PSA response rates in patients with positive CTC-based AR-V7 expression and collected liquid biopsies for genomic profiling. RESULTS: Cabazitaxel was found to be modestly effective, with only 12% of these patients obtaining a PSA response. Genomic profiling revealed that CTC-based AR-V7 expression was not associated with other known mCRPC-associated alterations. CTC-based AR-V7 status and dichotomised CTC counts were observed as independent prognostic markers at baseline. CONCLUSIONS: AR-V7 positivity predicted poor overall survival (OS). However, cabazitaxel-treated AR-V7 positive patients and those lacking AR-V7 positivity, who received cabazitaxel as standard of care, appeared to have similar OS. Therefore, despite the low response rate, cabazitaxel may still be an effective treatment in this poor prognosis, AR-V7 positive patient population.
引用
- Isebia KT, Mostert B, Belderbos BPS, et al. CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients. Eur J Cancer. 2022. PMID: 36323051. doi:10.1016/j.ejca.2022.09.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。